Mr. Doug Drysale reports

CYBIN ANNOUNCES THE DEVELOPMENT OF A SCALABLE PSYCHEDELIC FACILITATION TRAINING PROGRAM, EMBARKCT

Cybin Inc. has commenced the development of a streamlined, scalable version of its Embark training program, known as EmbarkCT. The Embark psychedelic facilitator training program was launched in October, 2021, and provides facilitators the foundational training needed to provide skillful and ethical care to work with psychedelic therapeutics. EmbarkCT marks an evolution of Embark and has been specifically developed with the goal of increasing Cybin's ability to effectively screen, qualify, train and certify facilitators to participate in future pivotal studies of its lead candidates, CYB003, a deuterated psilocybin analog for the potential treatment of major depressive disorder, and CYB004, a deuterated dimethyltryptamine (DMT) analog for the potential treatment of generalized anxiety disorder.

EmbarkCT is a streamlined training program designed for individuals with existing knowledge, skills and experience in psychedelic facilitation. The EmbarkCT training program will enable the company to effectively screen, qualify and train facilitators on a multisite, international level, to provide support and in-person monitoring for study participants receiving the company's investigational therapeutics in larger pivotal trials. Furthermore, Cybin's Embark Open Access (Embark OA), a free on-line training course for psychedelic facilitation, has laid the foundation for expanding access to training resources, and may serve as a bridge for facilitators to be enrolled in future Embark training programs and potentially participate in future Cybin-sponsored clinical trials.

"The evolution of the Embark training program to EmbarkCT enhances our capacity to deliver high-quality, scalable facilitator training suitable for a multisite, global clinical trial. We are excited about enacting this streamlined training model as we advance our clinical-stage programs towards pivotal studies," said Alex Kelman, PhD, Cybin's head of therapies.

As the company works toward scaling and accessibility for psychedelic facilitation, the company recognizes the American Medical Association's recently published language for new current procedural terminology (CPT) III codes, 0820T, 0821T and 0822T, for continuous in-person monitoring and intervention during psychedelic therapy administration. These CPT codes, which take effect Jan. 1, 2024, establish a standardized way to identify a procedure and are intended to allow data to be collected to support broader use or a potential U.S. Food and Drug Administration (FDA) approval process.

"As we continue to enhance our Embark facilitator training programs for future pivotal studies of Cybin's investigational psychedelic-based therapeutics, we are encouraged by the AMA's new CPT codes, which provide a clearer path for reimbursement and open the door to potentially incorporating psychedelic therapies and support models into the broader health care system," said Doug Drysdale, chief executive officer of Cybin.

About Embark

Embark is a transdiagnostic, flexible model of psychedelic facilitation training developed by Cybin and was born out of a desire to build upon the successes and shortcomings of previous psychological support approaches to create a model that enables participants to receive maximum benefit. Embark provides six clinical domains (existential-spiritual, mindfulness, body aware, affective-cognitive, relational and keeping momentum). Embark is built upon four care cornerstones: trauma-informed care, culturally competent care, ethically rigorous care and collective care. The Embark Open Access platform is the first and only free widely available open on-line course that offers psychedelic facilitation training for health care professionals and people interested in offering psychological support.

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions.

Cybin's goal of revolutionizing mental health care is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds.

We seek Safe Harbor.